Anne Whitaker - Mallinckrodt Plc Independent Director
| MNKDelisted Stock | USD 0.34 0.00 0.00% |
Director
Ms. Anne Clem Whitaker was appointed as Independent Director of the Company. has since 2017 served as chief executive officer and a member of the Board of Directors of KNOW Bio, LLC and Novoclem Therapeutics, Inc., a wholly owned subsidiary of KNOW Bio. Previously with Valeant Pharmaceuticals from 2015 to 2017, Ms. Whitaker served as executive vice president and company group chairman with responsibility for the company branded pharmaceutical segment including key businesses like Salix, Dendreon, and Orapharma as well as the Canadian and Western Europeregions. Prior to that she served as president, chief executive officer and a member of the Board of Directors at Synta Pharmaceuticals Corporationration from 2014 to 2015 as president ofNorth America pharmaceuticals and consumer health at Sanofi S.A. from 20112014 and in various roles at GSK, most recently as senior vice president and business unit head of the Cardiovascular, Metabolic and Urology Division since 2018.
| Age | 51 |
| Tenure | 6 years |
| Phone | 353 1 696 0000 |
| Web | https://www.mallinckrodt.com |
Mallinckrodt Plc Management Efficiency
Mallinckrodt Plc's management efficiency ratios could be used to measure how well Mallinckrodt Plc manages its routine affairs as well as how well it operates its assets and liabilities.The company has 3.07 B in debt with debt to equity (D/E) ratio of 1.44, which is OK given its current industry classification. Mallinckrodt Plc has a current ratio of 2.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Mallinckrodt Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Mallinckrodt Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mallinckrodt Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mallinckrodt to invest in growth at high rates of return. When we think about Mallinckrodt Plc's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| James Largent | Alimera Sciences | 67 | |
| Jijing Niu | Aurora Cannabis | N/A | |
| David Cohen | Journey Medical Corp | 53 | |
| Toai Nguyen | Aurora Cannabis | 58 | |
| Mark Brooks | Alimera Sciences | 50 | |
| Mary Szela | Alimera Sciences | 55 | |
| Frank Fallwell | SNDL Inc | N/A | |
| Matthew Fust | Journey Medical Corp | 53 | |
| Murray Garnick | Cronos Group | 58 | |
| Chris Schnarr | Canopy Growth Corp | 48 | |
| Eugene Bauer | Journey Medical Corp | 75 | |
| Scott LLB | Lucy Scientific Discovery | 54 | |
| Jason Dyck | Aurora Cannabis | N/A | |
| Peter Pizzo | Alimera Sciences | 50 | |
| Margaret Atkins | Aurora Cannabis | 63 | |
| Henry Stacpoole | Aurora Cannabis | N/A | |
| Angang Shen | Aurora Cannabis | 58 | |
| Jason Adler | Cronos Group | 46 | |
| Bruce Gates | Cronos Group | 56 | |
| Kathleen Sebelius | Journey Medical Corp | 69 | |
| Peter Stringham | Canopy Growth Corp | N/A | |
Management Performance
| Return On Equity | -1.11 | |||
| Return On Asset | -0.0029 |
Mallinckrodt Plc Leadership Team
Elected by the shareholders, the Mallinckrodt Plc's board of directors comprises two types of representatives: Mallinckrodt Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mallinckrodt. The board's role is to monitor Mallinckrodt Plc's management team and ensure that shareholders' interests are well served. Mallinckrodt Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mallinckrodt Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gary Phillips, Executive Vice President and Chief Strategy Officer | ||
| Steven Romano, Executive Vice President and Chief Scientific Officer | ||
| Mark Casey, Executive Vice President and Chief Legal Officer | ||
| JoAnn Reed, Independent Director | ||
| Virgil Thompson, Independent Director | ||
| Lisa French, Ex Officer | ||
| Stephen Welch, Ex Generics | ||
| Henriette Nielsen, Ex Officer | ||
| Steven MD, Ex Officer | ||
| Diane Gulyas, Independent Director | ||
| Joseph Zaccagnino, Independent Director | ||
| Paul Carter, Independent Director | ||
| David Carlucci, Independent Director | ||
| CPA CPA, Global Officer | ||
| George Kegler, CFO, Executive Vice President | ||
| Frank Scholz, Executive Vice President and Chief Operations and Digital Innovation Officer | ||
| David Norton, Independent Director | ||
| Hugh ONeill, Executive Vice President and President, Autoimmune and Rare Diseases | ||
| Martin Carroll, Independent Director | ||
| Steve Romano, Senior Vice President Chief Scientific Officer | ||
| Sigurdur Olafsson, Pres CEO | ||
| Mark Trudeau, CEO and President Director and Member of Portfolio Committee | ||
| Kneeland Youngblood, Independent Director | ||
| Bryan Reasons, Chief Financial Officer, Executive Vice President | ||
| J Carroll, Independent Director | ||
| Meredith Fischer, Senior Vice President - Communications and Public Affairs | ||
| Kassie Harrold, Ex Officer | ||
| Jason Goodson, Exec Devel | ||
| Terrance Carlson, Senior Vice President and General Counsel - Interim | ||
| Ian Watkins, Chief Human Resource Officer, Executive Vice President | ||
| Dagmar RosaBjorkeson, Chief Strategy and Corporate Development Officer | ||
| Melvin Booth, Independent Chairman of the Board | ||
| Raymond Furey, Senior Vice President Chief Compliance Officer | ||
| Angus Russell, Independent Non-Executive Chairman of the Board | ||
| Ronald Lloyd, Executive Vice President and President - Hospital Therapies | ||
| Karen Sheehy, Chief Compliance Officer | ||
| Matthew Harbaugh, CFO and Sr. VP | ||
| MichaelBryant Hicks, General Counsel | ||
| Carlos Paya, Independent Director | ||
| Anne Whitaker, Independent Director | ||
| Mark Tyndall, Chief VP |
Mallinckrodt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mallinckrodt Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.11 | |||
| Return On Asset | -0.0029 | |||
| Profit Margin | (0.83) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 2.62 B | |||
| Shares Outstanding | 13.29 M | |||
| Shares Owned By Insiders | 10.09 % | |||
| Shares Owned By Institutions | 96.64 % | |||
| Number Of Shares Shorted | 1.79 M | |||
| Price To Earning | 1.09 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mallinckrodt Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mallinckrodt Plc's short interest history, or implied volatility extrapolated from Mallinckrodt Plc options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Mallinckrodt Stock
If you are still planning to invest in Mallinckrodt Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mallinckrodt Plc's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |